Status:
COMPLETED
A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease
Lead Sponsor:
Bausch & Lomb Incorporated
Conditions:
Dry Eye Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
A dose ranging study to evaluate safety and efficacy of bromfenac ophthalmic solution in dry eye disease.
Eligibility Criteria
Inclusion
- Be of either gender and any race 18 years or older
Exclusion
- Have a local or systemic disease that could interfere with the assessment of safety or efficacy or that is likely to result in early discontinuation from the study
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
840 Patients enrolled
Trial Details
Trial ID
NCT01212471
Start Date
September 1 2010
End Date
December 1 2011
Last Update
September 4 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ISTA Pharmaceuticals, Inc.
Irvine, California, United States, 92618